On August 29, 2023, the Centers for Medicare and Medicaid Services (CMS) announced the first ten prescription drugs that will be subject to price controls in Medicare under the Inflation Reduction Act (IRA): Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and various forms of insulin. Two of those drugs, Enbrel and Stelara, were also among the five drugs selected by the Colorado Prescription Drug Affordability Board (PDAB) for affordability review and potential imposition of an upper payment limit (UPL).
CBSA continues to work directly with policymakers, collaborate with our state and national advocacy partners, and use our voice and communications platforms to emphasize our concerns about the unintended consequences of the flawed policies and implementation of government price controls on prescription drugs. Most recently, CBSA signed on to a letter from We Work for Health to the Colorado Congressional Delegation.
